BD211

GENETIC3 trials

Sponsors

Shanghai BDgene Co., Ltd.

Conditions

β-thalassemiaβ-thalassemia Major

Phase 1

A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major

RecruitingNCT06465550

Shanghai BDgene Co., Ltd.β-thalassemia

Start: 2024-01-05End: 2026-12-31Target: 9Updated: 2024-06-24

Unknown Phase

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

RecruitingNCT05773729

Shanghai BDgene Co., Ltd.β-thalassemia

Start: 2023-09-15End: 2026-10-31Target: 10Updated: 2024-06-14

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

RecruitingNCT05776173

Shanghai BDgene Co., Ltd.β-thalassemia Major

Start: 2023-08-10End: 2026-10-31Target: 10Updated: 2024-06-14